Search results
25 sie 2023 · Heart failure with preserved ejection fraction is increasing in prevalence and is associated with a high symptom burden and functional impairment, especially in persons with obesity. No...
30 wrz 2020 · The explanatory variables in the model were randomized treatment (semaglutide or comparator), baseline CV risk score (from the CV risk prediction model derived from the LEADER data as described above) and the interaction between treatment and CV risk score.
People with heart failure with preserved ejection fraction who received a weekly 2.4-mg injection of semaglutide for 52 weeks experienced more substantial improvements in symptoms and physical function than those who received a placebo, according to a randomized clinical trial involving 529 participants with obesity.
6 kwi 2024 · Among patients with obesity-related heart failure with preserved ejection fraction and type 2 diabetes, semaglutide led to larger reductions in heart failure–related symptoms and physical...
25 sie 2023 · In patients with heart failure with preserved ejection fraction and obesity, treatment with semaglutide (2.4 mg) led to larger reductions in symptoms and physical limitations, greater improvements in exercise function, and greater weight loss than placebo.
11 lis 2023 · In patients with preexisting cardiovascular disease and overweight or obesity but without diabetes, weekly subcutaneous semaglutide at a dose of 2.4 mg was superior to placebo in reducing the...
16 lis 2023 · New evidence suggests that semaglutide, sold as Ozemipc or Wegovy, could have far-reaching beneficial effects for cardiovascular health and heart failure.
